The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients is a research paper published in Journal of Geriatric Oncology (2023). On theSindex it has a DataRank of 0.693. It has been cited 18 times, with 15 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.442
From this paper's citation signal
Citation Network Contribution
0.251
From 13 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 15 citers.
NCI NIH HHS
Grant: UG1 CA233253
NCI NIH HHS
Grant: UG1 CA233320
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: UG1 CA233302
NCI NIH HHS
Grant: UG1 CA189828
NCI NIH HHS
Grant: UG1 CA233328
NCI NIH HHS
Grant: U10 CA180794
NCI NIH HHS
Grant: UG1 CA189956
FWCI
2.05
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
Additional file 1 of A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)